NCT01693939已完成4 期
A Single Center Prospective Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap
Durrie Vision1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2012年2月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Flap Thickness
研究概览
简要总结
The purpose of this study is to document the programmed flap thickness to achieved flap thickness using the FS200 femtosecond laser in performing LASIK procedure. The FS200 Femtosecond laser is a precision surgical device that is used to create a flap in a FDA approved LASIK procedure.
详细描述
The objective of this study is to evaluate the thickness of the corneal flap created with the FS 200 Femtosecond laser flap during the LASIK procedure using the Visante and OptiVue OCT ultrasound devices.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The following are requirements for a potential study patient's inclusion into the study:
- •Male or female in good general health, 18 years of age or older at the time of the pre-operative examination
- •Patient must be able to read, comprehend and willing to give HIPPA and informed consent
- •Patient is planning to undergo a bilateral LASIK procedure
- •Both eyes must have a manifest refractive error from -1.00 to -7.00D spherical equivalent with less than or equal to 3.00 D of refractive astigmatism as expressed in spectacle minus cylinder form
- •Both eyes must have a BSCVA of 20/25 or better
- •Both eyes must demonstrate refractive stability confirmed by clinical records or previous glasses. Refractive stability shall be documented by a change of less than or equal to 0.50 diopter per year (sphere and cylinder) or as documented by clinical judgment by the investigator.
排除标准
- •The following are exclusion criteria for study patients in this study:
- •A patient with evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye
- •A patient requiring the use of any ocular drop(s) and/or medication(s) in either eye during the study period with the exception of ocular drops and/or medications provided by the investigator
- •A patient having any surgical procedure within a week preceding the scheduled LASIK surgery
- •A patient with any UNCONTROLLED systemic disease (i.e., a potential patient in whom therapy for a systemic disease is not yet stabilized )
- •A patient with a history of prior intraocular or corneal surgery (including cataract extraction), clinically significant ophthalmic disease or abnormality (including, but not limited to, uncontrolled clinically significant blepharitis, clinically significant recurrent corneal erosion, clinically significant dry eye syndrome, clinically significant lens opacity, evidence of clinically significant trauma (including scarring inside the visual axis), or evidence of glaucoma or propensity for narrow angle glaucoma in either eye
- •A patient with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, may increase the risk associated with study participation or may interfere with the interpretation of study results
- •A patient with a history of any of the following medical conditions, or any other condition that could affect wound healing: uncontrolled diabetes, collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis
- •A female patient who is pregnant, nursing, planning a pregnancy during the study, or thinks she may be pregnant at the start of the study
- •Current participation or participation within 30 days prior to the start of this study in a drug or other investigational device research study.
研究组 & 干预措施
FS200 Femtosecond Laser
Other
The LASIK flap will be created using the FS200 Femtosecond Laser
干预措施: FS200 Femtosecond Laser (Device)
结局指标
主要结局
Flap Thickness
时间窗: 1 Week Postoperative visit
The flap thickness will be measured one week postoperative using the Visante OCT and the Optivue OCT devices
次要结局
- Change in Uncorrected Visual Acuity at 1 Day, 1 Week, and 1 Month Postoperatively(Postoperatively 1 month)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
TARGET Post-Approval StudyComplex Regional Pain Syndrome (CRPS)NCT02800863Abbott Medical Devices426
Unknown
不适用
Clinical Utility for Ion Endoluminal SystemLung DiseasesPulmonary NoduleLung CancerNCT03893539Intuitive Surgical365
已完成
2 期
A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg UlcersVenous Leg UlcerDiabetic Foot UlcerNCT04817228MediWound Ltd12
已完成
不适用
A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02419859CeQur Corporation20
Unknown
不适用
Post-market Registry to Assess the Clinical Performance and Safety of the Passeo-18 Lux in Infrainguinal ArteriesDisease, Peripheral ArteryAngioplasty, BalloonNCT05175703Ajou University School of Medicine200